European Medicines Agency adopted a change to an indication for eribulin

The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending a variation to the terms of the marketing authorisation for the medicinal product eribulin (Halaven). Halaven is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Read more here.